The proposed Human Genome Project II could set in motion a 'paradigm shift' toward more precise public health, and a global research alliance A group of Chinese researchers has launched an ...
Andy Makiv has been appointed as Godolphin Australia's new managing director.
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage ...
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...
ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding perioperative durvalumab (Imfinzi) to neoadjuvant ...
Prime Minister Narendra Modi will inaugurate the second phase of the Ahmedabad-Gandhinagar Metro on September 16. This new ...
Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Hidradenitis Suppurativa.
This sequential expression followed the phases of the traditional cell cycle: G0/G1 (the cell grows larger), S (the cell replicates its DNA), and G2/M (the cell prepares for division and then splits).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback